Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof
Inventors
Zhao, Jian • ZHU, Yunfei • Chen, Mi
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are somatostatin subtype-2 receptor (SST2R) targeted therapeutics that target tumor cells expressing SST2R and their use in the treatment of cancer.
Core Innovation
The disclosure relates to SST2-targeted small-molecule drug conjugates comprising a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof. An aminopiperidine-substituted pyridyl-benzimidazole targeting moiety is connected via connecting group L to a payload moiety Rd comprising a chemotherapeutic agent. The connecting group L comprises an optional spacer L1 and an optional linker L2, wherein at least one of L1 or L2 is present.
The disclosed architectures encompass polyethylene glycol segments, ether chains, disulfide linkages, amide bonds, and amino-acid or peptide sequences, as well as sugar-bearing motifs. Linkers are configured as non-cleavable or cleavable under acidic, reducing, hypoxic, or enzyme-rich conditions. Payloads include mertansine, exatecan, auristatin derivatives such as monomethyl auristatin E and monomethyl auristatin F, and chelator-bound diagnostic or therapeutic radionuclides.
Reported biological data characterize SSTR2 cAMP modulation, cellular internalization, and antiproliferative activity in H524 small-cell lung cancer cells. The disclosure demonstrates tumor delivery of monomethyl auristatin E and receptor-specific tumor uptake of radiolabeled conjugate. Conjugate embodiments facilitate tumor-directed delivery to target tumors expressing peptide-hormone G protein-coupled receptors including somatostatin receptor subtype 2.
Claims Coverage
The patent claims define three independent claims directed to a Formula (I) conjugate compound and two defined groups of depicted compounds, alongside dependent claims specifying linker, payload, and treatment options. Three inventive features are identified.
Formula (I) compound with chemotherapeutic-agent payload
Independent claim 1 covers a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof, wherein payload moiety Rd comprises a chemotherapeutic agent connected through L, where L is -L1-L2- and at least one of optional spacer L1 or optional linker L2 is present.
First group of selected depicted compounds
Independent claim 19 covers a compound, or a pharmaceutically acceptable salt thereof, selected from a first group consisting of depicted compounds.
Second group of selected depicted compounds
Independent claim 20 covers a compound, or a pharmaceutically acceptable salt thereof, selected from a second group consisting of depicted compounds.
The independent claims cover a structurally defined Formula (I) chemotherapeutic conjugate and two groups of depicted compounds, each including pharmaceutically acceptable salt coverage. Dependent claims further define specific peptide linkers, chemotherapeutic payloads, and methods of treating cancer in a mammal.
Stated Advantages
Compared with piperazine-linked controls, ethylenediamine-linked compounds show improved internalization and H524 small-cell lung cancer cell antiproliferative activity.
D-amino-acid linkers are noted as potentially reducing immunogenicity and nonspecific proteolysis.
The disclosure proposes improved tumor-directed delivery over nonspecific chemotherapy.
Documented Applications
Treating cancer in a mammal by administering an effective amount of a claimed compound or its pharmaceutically acceptable salt.
Chelator-bound diagnostic radionuclides for PET or SPECT imaging.
Therapeutic radionuclides for radiotherapy and treatment of tumors expressing peptide-hormone G protein-coupled receptors, including somatostatin receptor subtype 2 and gastroenteropancreatic neuroendocrine tumors.
Interested in licensing this patent?